A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Riluzole (TIGLUTIK)

Benzothiazole class · 4 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval2013-06-18
Generic availableYes · 4 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$19.0M in CY2024 Part D spend78K claims · 19K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.269/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.269
Across all dosage forms in distribution.
Highest NADAC
$0.269
Range is tight.
Plans with PA
35 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Riluzole used for?

Riluzole is a Benzothiazole medication tracked in Medicare Part D.

Is there a generic for Riluzole?

Yes. 5 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Riluzole?

Across 329 Part D plans, Riluzole averages $0.269/unit (NADAC). Lowest available: $0.269/unit. Highest in distribution: $0.269/unit.

Is Riluzole on the FDA shortage list?

Yes. Riluzole is currently listed as an active FDA shortage.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.